Vilon Research: What 607 Studies Show (2026) | RetatrutideCompare

Vilon — 607 studies indexed on PubMed. Proposed to modulate gene expression in immune tissues and extend lifespan in murine models. Half-life: Minutes. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Vilon?

There are approximately 607 studies indexed on PubMed that mention Vilon (KE, Lys-Glu), based on a search last updated 2026-06-18.

Is Vilon FDA-approved?

FDA status: Not FDA-approved.

How does Vilon work?

Proposed to modulate gene expression in immune tissues and extend lifespan in murine models.

Proposed to modulate gene expression in immune tissues and extend lifespan in murine models.

Reference facts

Also known as
KE, Lys-Glu
Category
Khavinson Bioregulators
Mechanism of action
Proposed to modulate gene expression in immune tissues and extend lifespan in murine models.
Targets
Thymic gene expression (proposed)
Indications under research or approved
Russian gerontology research
Regulatory status (reference entry)
Not FDA-approved
Half-life
Minutes
Sequence
KE
Sequence notes
Dipeptide developed by Khavinson group as a thymic immunomodulator bioregulator.
Molecular weight (Da)
275
First reported
1995

Primary References

Explore research articles about Vilon

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.